Order Article Reprints

De Meza MM, Blokx WAM, Bonenkamp JJ, Blank CU, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, De Groot JWB, Haanen JBAG, Hospers GAP, et al. Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis. Cancers. 2023; 15(2):409. https://doi.org/10.3390/cancers15020409

De Meza, Melissa M., Willeke A. M. Blokx, Johannes J. Bonenkamp, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Jan Willem B. De Groot, John B. A. G. Haanen, Geke A. P. Hospers, and et al. 2023. "Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis" Cancers 15, no. 2: 409. https://doi.org/10.3390/cancers15020409

De Meza, M. M., Blokx, W. A. M., Bonenkamp, J. J., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Boers-Sonderen, M. J., De Groot, J. W. B., Haanen, J. B. A. G., Hospers, G. A. P., Kapiteijn, E., Van Not, O. J., Piersma, D., Van Rijn, R. S., Stevense-den Boer, M., Van der Veldt, A. A. M., Vreugdenhil, G., Van den Eertwegh, A. J. M., Suijkerbuijk, K. P. M., & Wouters, M. W. J. M. (2023). Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis. Cancers, 15(2), 409. https://doi.org/10.3390/cancers15020409